The Atlantis China Healthcare Fund is the world’s first dedicated Chinese healthcare fund and aims to exploit the opportunities available in the healthcare industry resulting from the country’s rapid economic development.
The Fund places emphasis on both value and growth in order to target long term capital gains with an absolute return style and a concentrated portfolio.
The Fund invests principally in Hong Kong listed H-shares, Red-chips, P-chips, as well as A-shares (via listed and unlisted p-notes). It covers a broad investment mandate across a range of Chinese healthcare subsectors. This includes companies principally engaged in pharmaceuticals, bio-technology, medical devices, healthcare providers and ownership or management of hospitals/nursing homes, health maintenance organisations in China, or in other health related industries (such as environmental protection which includes alternative energy water treatment and waste management) in China.
The Fund Managers generally employ a combination of top-down macro views and bottom-up approach to stock-picking, based on intensive fundamental research. Many other factors will be assessed and taken into consideration in identifying suitable companies for the portfolio. The Fund also use trading strategy to capture attractive valuations within a shorter term investment horizon.
Please refer to the investment terms for more information.
Source of performance: Bloomberg. Please note that investment involves risks. The unit price of the Fund may go down as well as up and the past performance presented is not indicative of future performance and investors may not get back the full amount invested. Investors should refer to the “Risk Factors” section of the Fund Prospectus for further details prior to subscription for units of the Fund.